A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

Inclusion criteria

• ≥18 years of age;
• Solid Tumor confirmed by histology or cytology;
• ECOG score is 0 or 1;
• An expected survival of ≥ 12 weeks;
• At least one measurable lesion according to RECIST v1.1 criteria;
• Have adequate renal and hepatic function;
• Patients voluntarily joined the study and signed informed consent.

Exclusion criteria

• With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer;
• Patients have major surgical procedures or radiotherapy / chemotherapy within 4 weeks before the first medication;
• History of immunodeficiency;
• Clinically significant cardiovascular diseases;
• Known or suspected interstitial lung disease;
• Known hereditary or acquired bleeding thrombotic tendency;
• Active hepatitis and liver cirrhosis;
• Known allergic history of the drug components of this protocol;
• History of neurological or psychiatric disorders.